11 results
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Intermediates and End-Product ... Heme #Pathophys #Honc ... Synthesis #Porphyria #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Survival #EBM #Honc ... #Osimertinib #NSCLC ... #Survival #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Lung Cancer #EBM #Honc ... #ALKPositive #NSCLC ... VisualAbstract #NEJM
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer - Progression-free Survival in the Intention-to-Treat Population.
#EBM #Honc #PACIFIC ... #Durvalumab #NSCLC ... #NEJM
Diagnostic Algorithm for Non–Small-Cell Lung Cancer (NSCLC). The upper portion of the algorithm shows the morphologic
Non–Small-Cell Lung Cancer (NSCLC ... classification of NSCLC ... #Diagnosis #Honc ... #Algorithm #NSCLC ... #PDL1 #NEJM
Hemolysis in Hereditary Spherocytosis. Panel A shows the structure of a normal red cell and a
Pathophysiology #Honc ... #IM #Spherocytosis ... HereditarySpherocytosis #NEJM
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis - Incidence of New Vertebral, Clinical,
#PrimaryCare #Endo ... #IM #Romosozumab ... #Alendronate #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
Pathophysiology #IM ... #Honc #Pharm #GVHD ... Immunosuppression #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
and Secondary End ... Points #EBM #Neuro #IM ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
and Secondary End ... Points #EBM #Neuro #IM ... CalcitoninGeneRelatedPeptideAntibody #NEJM